Third Opinion Trial Synopsis
This study is being done to give people with a type of cancer called multiple myeloma ongoing access to a treatment called daratumumab. It is also allowing people with a less serious form of the cancer called smoldering multiple myeloma to have access to this treatment. The study is open to all participants, no matter which group they were in during previous daratumumab studies. It is also giving access to participants who were in the daratumumab group of non-daratumumab studies. The study will collect information about the safety of the treatment over a long period of time.

Trial Summary
The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma benefiting from treatment in certain Janssen Research and Development (R\&D) studies that use daratumumab as part of the study treatment regimen: access for all participants regardless of treatment group in daratumumab studies and access to participants in daratumumab-containing arms in the non-daratumumab studies will be allowed from studies which have reached clinical cutoff for final analysis. Certain long-term safety data will continue to be collected from study participants.